Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724434 | 0.86 | ALDH1A1 (0.42) | CHEK2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL723473 | 0.86 | CHEK2 (0.41) | CHEK2ALDH1A1CNR2NPC1SMN1; SMN2 | |
| SCHEMBL724208 | 0.86 | ALDH1A1 (0.48) | CES2CES1CHEK2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL724182 | 0.85 | ALDH1A1 (0.41) | CHEK2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL786732 | 0.84 | CHEK2 (0.40) | CHEK2ALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL724202 | 0.80 | HSD17B14 (0.42) | CHEK2CNR2CNR1 | |
| SCHEMBL8963515 | 0.79 | NISCH (0.42) | CHEK2ALDH1A1GRM2GAASMN1; SMN2 | |
| SCHEMBL14952963 | 0.77 | NOTUM (0.47) | CHEK2RAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1078329 | 0.77 | CHEK2 (0.48) | CHEK2ALDH1A1RAB9AL3MBTL1GRM2 | |
| SCHEMBL15180532 | 0.77 | ALDH1A1 (0.49) | CHEK2ALDH1A1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CHEK2 284/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CHEK2 284/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | CES2 2621/4885CES1 3402/4885CHEK2 2076/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | CES2 876/4885CES1 1430/4885CHEK2 1633/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CHEK2 284/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CHEK2 284/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | CES2 876/4885CES1 1430/4885CHEK2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.